Construction and immunogenicity of Salmonella vaccine vector expressing HIV-1 antigen and MCP3

Acta Microbiologica et Immunologica Hungarica

Volumn 56, Issue 4, 2009, Pages 403-415

  Bachtiar, E ^a,b   Coloe, P ^a   Smooker, P ^a  

^a RMIT UNIVERSITY   (Australia)

^b UNIVERSITY OF INDONESIA   (Indonesia)

Author keywords

DNA vaccine; HIV; MCP3; Recombinant; Salmonella

Indexed keywords

ANTIGEN P24; BACTERIAL VECTOR; DNA VACCINE; IMMUNOGLOBULIN A; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 3; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DNA IMMUNIZATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; SALMONELLA ENTERICA; SALMONELLA ENTERICA SEROTYPE TYPHIMURIUM; SEROTYPE; SPLEEN CELL; VACCINATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; SALMONELLA; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;

EID: 75149158602     PISSN: 12178950     EISSN: 15882640     Source Type: Journal    
DOI: 10.1556/AMicr.56.2009.4.10     Document Type: Article

References (25)

1. Vecino, W. H. et al.: Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HIV. Immunol. Lett. 82(3), 197-204 (2002).
2. Fouts, T. R. et al.: Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1. FEMS Immunol. Med. Microbiol. 37(2-3), 129-134 (2003).
3. Fouts, T. R. et al.: Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120. Vaccine 13(17), 1697-1705 (1995).
4. Biragyn, A. et al.: DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood 100(4), 1153-1159 (2002).
5. Shata, M. T. et al.: Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine 20(3-4), 623-629 (2001).
6. Nasioulas, G. et al.: Molecular analysis of the full-length genome of HIV type 1 subtype I: evidence of A/G/I recombination. AIDS Res. Hum. Retroviruses 15(8), 745-758 (1999).
7. Frankel, A. D., Young, J. A.: HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem. 67, 1-25 (1998).
8. Dimmock, N. J.: Neutralization of animal viruses. Curr. Top. Microbiol. Immunol. 183, 1-149 (1993).
9. Safrit, J. T., Koup, R. A.: The immunology of primary HIV infection: which immune responses control HIV replication? Curr. Opin. Immunol. 7(4), 456-461 (1995).
10. Harrer, T. et al.: Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res. Hum. Retroviruses 12(7), 585-592 (1996).
11. Rowland-Jones, S. et al.: HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1(1), 59-64 (1995).
12. Klein, M. R. et al.: Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181(4), 1365-1372 (1995).
13. McAdam, S. et al.: Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection. Aids 12(6), 571-579 (1998).
14. Bachtiar, E. W.: Enhancement of immune responses of Salmonella-delivered foreign antigen. In: Biotechnology and Environmental Biology. RMIT University Melbourne Australia, Melbourne, p. 270, 2005.
15. Cheminay, C. et al.: Migration of Salmonella typhimurium - harboring bone marrow - derived dendritic cells towards the chemokines CCL19 and CCL21. Microb. Pathog. 32(5), 207-218 (2002).
16. Fairweather, N. F. et al.: Use of live attenuated bacteria to stimulate immunity. Res. Microbiol. 141(7-8), 769-773 (1990).
17. Rowland-Jones, S. L. et al.: Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors. Immunol. Lett. 66(1-3), 9-14 (1999).
18. Kim, J. J. et al.: In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J. Immunol. 158(2), 816-826 (1997).
19. Boyer, J. D. et al.: HIV-1 DNA vaccines and chemokines. Vaccine 17 Suppl. 2, S53-64 (1999).
20. Spreng, S. et al.: Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing protective listerial epitopes within a surface-exposed loop of the TolC-protein. Vaccine 21(7-8), 746-752 (2003).
21. Pogonka, T. et al.: A single dose of recombinant Salmonella typhimurium induces specific humoral immune responses against heterologous Eimeria tenella antigens in chicken. Int. J. Parasitol. 33(1), 81-88 (2003).
22. McConkey, S. J. et al.: Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9(6), 729-735 (2003).
23. Baud, D. et al.: Immunogenicity against human papillomavirus type 16 virus-like particles is strongly enhanced by the PhoP(c) phenotype in Salmonella enterica, Serovar typhimurium. Infect. Immun. 72(2), 750-756 (2004).
24. Steinman, R. M., Pope, M.: Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109(12), 1519-1526 (2002).
25. Rainczuk, A. et al.: Induction of specific T-cell responses, opsonizing antibodies, and protection against Plasmodium chabaudi adami infection in mice vaccinated with genomic expression libraries expressed in targeted and secretory DNA vectors. Infect. Immun. 71(8), 4506-4515 (2003)